US3914158A - Antibiotic production - Google Patents
Antibiotic production Download PDFInfo
- Publication number
- US3914158A US3914158A US367661A US36766173A US3914158A US 3914158 A US3914158 A US 3914158A US 367661 A US367661 A US 367661A US 36766173 A US36766173 A US 36766173A US 3914158 A US3914158 A US 3914158A
- Authority
- US
- United States
- Prior art keywords
- culture medium
- cephamycin
- organism
- medium
- toyocamycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G11/00—Antibiotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/874—Pseudomonas
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/886—Streptomyces
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/909—Vibrio
Definitions
- This invention relates to the novel production by fermentation of useful antibiotic substances that heretofore have been reported in the prior art. More particularly, this invention relates to the preparation, by cultivating under controlled conditions a hitherto undescribed strain of Streptomyces albogriseolus, of the known useful antibiotics:
- cephamycin C a. toyocamycin [Merck Index, eighth Ed., 1968, pages 1062-1063] and b. 7,B-(D-S-amino-5-carboxyvaleramido)-3- (carbamoyloxymethyl )-7-methoxy-3-cephem-4- carboxylic acid, hereinafter referred to as cephamycin C
- cephamycin C Belgium Pat. No. 764,160; .l.A.C.S. 93, May 5, 1971, pgs. 2308-2312 (compound 4); Chap. ISCephalosporins and Penicillins, Chemistry and Biology, ed. by Flynn, Academic Press, NY. (1972) (compound 5); Stapley et al., Antibiotic Agents and Chemotherapy 2, pgs. 122-131 (1972)].
- the antibiotics indicated above are co-produced by cultivating under controlled conditions a new strain of actinomycete designated at MA-4256 in the culture collection of Merck & Co., Inc., Rahway, NJ.
- the novel organism capable of producing the antibiotic products has been placed on permanent deposit without restriction as to availability with the culture collection of the Northern Utilization Research and Development Division, Agricultural Research Service, U.S. Department of Agriculture (Formerly Northern Regional Research Laboratories), Peoria, 111. 61604 and is available to the public under culture No. NRRL 5735.
- the novel microorganism utilized in the practice of the invention is a previously unknown strain of a specie of actinomycete known as Streptomyces albogriseolus.
- the original isolate was obtained from soil as a single colony on an agar plate. It may be grown in any one of the media described below.
- Sporophores form many closed, compact spirals of more than 10 spores each. Spores are spherical to slightly oval-0.9g. diameter and 0.9;. wide X 1.2a long. Sporulation seen on Czapek-Dox agar and synthetic starch agar.
- Aerial mycelium--Moderate grayish white to pale gray edged with medium gray. Good sporulation.
- Vegetative growth--Moderate growth ring, tan Vegetative growth--Moderate growth ring, tan.
- the Streptomyces albogriseolus culture (MA-4256) was also tested for its ability to utilize or assimilate various carbohydrates by growing the microorganism in a basal synthetic medium (T. G. Pridham and D. Gottlieb, Journal of Bacteriology, Vol. 56, page 107, 1948) which contains 1% of the carbohydrate at 28C. for 3 weeks.
- the following table indicates the utilization or assimilation of these carbohydrate sources by the Streptomyces albogriseolus culture (MA-4256). The explanation of the symbols in the table are as follows: indicates good growth, 2 indicates poor growth and indicates no growth on the particular carbohydrate.
- the antibiotics toyocamycin and cephamycin C are produced during the aerobic fermentation of suitable aqueous nutrient mediums under controlled conditions via inoculation with the Streptomyces albogriseolus culture [VIA-4256.
- Aqueous mediums such as those employed for the production of other antibiotics are also suitable for producing the antibiotics described above.
- Such mediums contain sources of carbon and nitrogen assimilable by the microorganism and inorganic salts.
- carbohydrates such as sugars, for example, glucose, arabinose, maltose, Xylose, mannitol and the like and starches such as grains, for example, oats, rye, corn starch, corn meal and the like can be used either alone or in combination as sources of assimilable carbon in the nutrient medium.
- the exact quantity of the carbohydrate source or sources utilized in the medium depend in part upon the other ingredients of the medium but, in general, the amount of carbohydrate usually varies between about 1% and 6% by weight of the medium.
- These carbon sources can be used individually or several such carbon sources may be combined in the medium.
- any proteinaceous material may be used as a nitrogen source in the fermentation process.
- Suitable nitrogen sources include, for example, yeast hydrolysates, yeast autolysate, soybean meal, hydrolysates of casein, corn steep liquor, distillers solubles or tomato paste and the like.
- the sources of nitrogen either alone or in combination, are used in amounts ranging from about 0.2 to 6% by weight of the aqueous medium.
- the nutrient inorganic salts which can be incorporated in the culture media are the customary salts capable of yielding sodium, potassium, ammonium, calcium, phosphate, sulfate, chloride, carbonate, and like ions.
- Difco Yeast Extract 10.0 g. Glucose 10.0 g. Phosphate Buffer* 2.0 ml. MgSO 7H 0 0.05 g. Distilled water 1000.0 ml. Difco Agar 25.0 g.
- Dextrose 10.0 g. Asparagine 1.0 g. K HPO 0.1 g. MgSO, 7H O 0.5 g. Yeast Extract 0.5 g. Trace Element Mix No. 2* 10.0 ml. Distilled H O 1000.0 m1.
- FeSO -7H O 1.0 g. MnSO, H O 1.0 g. CuCl 2H O 25.0 mg.
- Yeast Autolysate (Ardamine) 10.0 g Glucose 10.0 g. Phosphate Buffer* 2.0 ml. MgSO, 7H 0 0.5 g. Distilled H O 1000.0 ml.
- Corn Steep Liquor (wet basis) 40.0 g. Dextrose 20.0 g. NaCl 2.5 g. MgSO 7H O 0.5 g
- Distillers Solubles Distilled Water The fermentation is carried out at temperatures ranging from about 20C. to 37C., but for optimum results it is preferable to conduct the fermentation at tempera tures of from about 24C. to 32C.
- the pH of the nutrient mediums suitable for growing the Streptomyces albogriseolus culture (MA-4256) and producing the antibiotic products should be in the range of from about 6.0 to about 8.0.
- Fermentation is conveniently carried out by inoculating a suitable nutrient medium with the antibioticproducing culture and permitting the fermentation to proceed at a constant temperature of about 28C. on a shaker for several days. At the end of the incubation period the mycelium is removed and the supernatant liquid is assayed.
- this fermentation is conducted in a sterilized flask via a one, two, three or four stage seed development.
- the nutrient medium for the seed stage may be any suitable combination of carbon and nitrogen sources, as for example, any one of Media I-XI described above.
- the seed flask is shaken in a constant temperature chamber at about 28C. for a period of from 1 to about 3 days and a portion of the resulting growth is used to inoculate either a second stage seed or the production medium.
- the nutrient medium is made up in the tank and sterilized by heating at temperatures of up to about C.
- the sterilized medium is inoculated with the producing culture and the fermentation is permitted to proceed for a period of several days as, for example, from 2 to 4 days while agitating and/or aerating the nutrient medium and maintaining the temperature at about 28C.
- the concentration of antibiotic activity in the culture medium can be followed readily during the fermentation period by testing samples of the culture medium for their inhibitory activity against the growth of organisms known to be inhibited by the presence of the antibiotics produced in accordance with the practice of the invention.
- the organisms Vibrio percolans ATCC 8461 and Pseudomonas stutzeri ATCC 1 1607 have been found to be useful for this purpose.
- the testing of the samples can be carried out by the well-known turbidometric or disc-plate methods.
- EXAMPLE 1 A lyophilized tube of Streptomyces albogriseolus culture (MA-4256) was opened asceptically and the organism transferred to a sterile slant of Medium A.
- the Medium A has the following composition:
- the slant was incubated for seven days at 28C.
- the slant was stored in the cold for 2 weeks, at which time a sterile slant of Medium B was inoculated with a portion of the growth from the Medium A slant.
- the Medium B has the following composition:
- cephamycin C The presence and concentration of cephamycin C in the broth was determined by standard agar diffusion assays performed with 0.5-inch filter paper discs soaked in the broth and set on the surface of assay plates containing 10 ml. of nutrient agar (Difco) plus 0.2% yeast extract (Difco) medium seeded with the bacterial inoculum.
- the assay organism employed was 'Vibrio percplans (ATCC 8461 Filter paper discs are immersed into the diluted broths and placed on the surface of agar-containing Petri dishes that had been inoculated with the assay organism Vibrio percolans (ATCC 8461 Also placed on these Petri dishes are discs that had been dipped previously in standard solutions containing known concentrations of cephamycin C. The discs were incubated overnight at 28C and the diameters of the zones of inhibition recorded. The concentration of cephamycin C in the fermented broth is calculated by interpolation from the standard curve which relates zone diameter with the known concentrations of standard cephamycin C solutions. The assays of broth harvested after fermentation for 4 days showed an inhibition zone of 31.5 mm. diameter on plates seeded with Vibrio percolans (ATCC 8461). The broth potency was 42 ug/ml. as cephamycin C.
- EXAMPLE 2 Isolation of Cephamycin C
- the filtered broth (2 liters) obtained in accordance with Example 1 (pH 8.0) was adsorbed on 200 ml. of a strongly. basic anion exchange resin having a styrenedivinylbenzene matrix (Dowex 1 X 2 chloride cycle resin) and eluted with 5% aqueous sodium chloride.
- the eluate was collected in ml. fractions and assayed as described above.
- the active fractions of Dowex 1 eluate were combined and adjusted to pH 4.0 with dilute hydrochloric acid and adsorbed on 250 ml.
- Fractions 81 to 101 were combined and the pH adjusted to 8.2 with dilute sodium hydroxide. The solution was concentrated to a small volume to remove pyridine and the pH adjusted from 7.5 to 7.0 with HCl.
- Paper strip chromatography was carried out using Whatman No. 1 paper and n-butyl alcohol, acetic acid, methyl alcohol, water (4:1:1:2). The compound was detected by bioautographing against Vibrio percolans ATCC 8461 and Pseudomonas stutzeri ATCC 11607.
- NRRL 5735 (Rf 0.22) with activity against Vibrio percolans ATCC 8461 cannot be distinguished from cephamycin C.
- a method of producing an antibiotic mixture comprised of cephamycin C and toyocamycin which method comprises cultivating a cephamycin C and toyocamycin producing strain of Streptomyces albagriseolus in a culture medium containing assimilable sources of carbon and nitrogen under aerobic conditions until a substantial amount of said antibiotics are produced by said organism in the culture medium.
- a method according to claim 1 additionally comprising recovering cephamycin C from said culture medium.
- a method according to claim 1 additionally comprising recovering toyocamycin from said culture medium.
- a method of producing the antibiotic cephamycin C which method comprises cultivating a cephamycin C producing strain of Streptomyces albogriseolus in a culture medium containing assimilable sources of carbon and nitrogen under aerobic conditions until a substantial amount of said antibiotic is produced by said organism in the culture medium.
- a method according to claim 5 additionally comprising recovering cephamycin C from said culture medium.
- a method of producing the antibiotic toyocamycin which method comprises cultivating a toyocamycin producing strain of Streptomyces albogriseolus in a culture medium containing assimilable sources of carbon and nitrogen under aerobic conditions under a substantial amount of said antibiotic is produced by said organism in the culture medium.
- a method according to claim 8 additionally comprising recovering toyocamycin from said culture medium.
Abstract
Production of antibiotics cephamycin C and toyocamycin by fermentation of Streptomyces albogriseolus.
Description
United States Patent Stapley et al.
[ Oct. 21, 1975 ANTIBIOTIC PRODUCTION Inventors: Edward O. Stapley, Metuchen, N.J.;
Justo M. Mata, Madrid, Spain Assignee: Merck & Co., Inc., Rahway, NJ.
Filed: June 6, 1973 Appl. No: 367,661
Published under the Trial Voluntary Protest Program on January 28, 1975 as document no. B 367,661.
US. Cl 195/80 R Int. Cl. Cl2D 9/00 Field of Search..... 195/28 N, 80 R, 96, D16 1;
[56] References Cited UNITED STATES PATENTS 3,116,222 12/1963 Rao et a] 195/80 R 3,801,464 4/1974 Gorman et al. 195/80 R Primary Examiner-LioneI M. Shapiro Assistant ExaminerR. B. Penland Attorney, Agent, or Firm-Julian S. Levitt; J. Jerome Behan [S 7] ABSTRACT Production of antibiotics cephamycin C and toyocamycin by fermentation of Streptomyces albogriseolus.
10 Claims, No Drawings ANTIBIOTIC PRODUCTION This invention relates to the novel production by fermentation of useful antibiotic substances that heretofore have been reported in the prior art. More particularly, this invention relates to the preparation, by cultivating under controlled conditions a hitherto undescribed strain of Streptomyces albogriseolus, of the known useful antibiotics:
a. toyocamycin [Merck Index, eighth Ed., 1968, pages 1062-1063] and b. 7,B-(D-S-amino-5-carboxyvaleramido)-3- (carbamoyloxymethyl )-7-methoxy-3-cephem-4- carboxylic acid, hereinafter referred to as cephamycin C [Belgium Pat. No. 764,160; .l.A.C.S. 93, May 5, 1971, pgs. 2308-2312 (compound 4); Chap. ISCephalosporins and Penicillins, Chemistry and Biology, ed. by Flynn, Academic Press, NY. (1972) (compound 5); Stapley et al., Antibiotic Agents and Chemotherapy 2, pgs. 122-131 (1972)].
The antibiotics indicated above are co-produced by cultivating under controlled conditions a new strain of actinomycete designated at MA-4256 in the culture collection of Merck & Co., Inc., Rahway, NJ. The novel organism capable of producing the antibiotic products has been placed on permanent deposit without restriction as to availability with the culture collection of the Northern Utilization Research and Development Division, Agricultural Research Service, U.S. Department of Agriculture (Formerly Northern Regional Research Laboratories), Peoria, 111. 61604 and is available to the public under culture No. NRRL 5735.
The novel microorganism utilized in the practice of the invention is a previously unknown strain of a specie of actinomycete known as Streptomyces albogriseolus. The original isolate was obtained from soil as a single colony on an agar plate. It may be grown in any one of the media described below.
The cultural characteristics of MA-4256 have been compared with culture descriptions of known species in Bergeys Manual of Delerminative Bacteriology, seventh Edition (Williams and Wilkins, 1957), The Actinomycetes, Vol. 2, S. A. Waksman (Williams and Wilkins, 1961), Cooperative Description of Type Cultures of Streptomyces", Elwood B. Shirling and David B. Gottlieb, Part 1, International Journal of Systematic Bacteriology 17, 315 (1967), Part II, 18, 69 (1968), Part 111, 18, 279 (1968), and Part IV, 19, 391 (1969).
Based on this comparison the culture was found to belong to the species Streptomyces albogriseolus as described by Waksman. There is a slightly different re sponse in carbohydrate utilization from that given in the Shirling and Gottlieb study. MA-4256 utilized glucose, sucrose, xylose, inositol, mannitol, fructose and raffinose for growth and grew poorly on rhamnose. The culture described in the cooperative study of Shirling and Gottlieb utilized glucose, xylose, sucrose (though growth was less abundant than the others), inositol, mannitol, fructose and rhamnose but showed no growth or only a trace of growth on raffinose. However, these differences in carbohydrate utilization are considered to be a strain characteristic insufficient to determine a new species.
Accordingly, this culture has been named Streptomyces albogriseolus, strain MA-4256.
The following is a general description of the organism based on the diagnostic characteristics observed. All of the readings reported below were taken after 3 weeks incubation at 28C., except where otherwise noted.
Cultural Characteristics of MA-4256 Morphology:
Sporophores form many closed, compact spirals of more than 10 spores each. Spores are spherical to slightly oval-0.9g. diameter and 0.9;. wide X 1.2a long. Sporulation seen on Czapek-Dox agar and synthetic starch agar.
Tomato-Paste-Oatmeal Agar:
Vegetative growth--Reverse--Medium brownishorange.
Aerial mycelium--Moderate, white.
Soluble pigment--None.
Czapek-Dox Agar:
Vegetative growth--Reverse-grayed cream.
Aerial mycelium--Moderate, grayish white to pale gray edged with medium gray. Good sporulation.
Soluble pigment--None.
Egg Albumin Agar:
Vegetative growth--Reverse-tannish yellow.
Aerial mycelium--Moderate, cream-colored.
Soluble pigment--Very light brown. Glycerol-Asparagine Agar:
Vegetative growth--Reverse--medium golden yellow.
Aerial mycelium--Cream-colored.
Soluble pigment--Very light brown.
Synthetic Starch Agar:
Vegetative growth--Reverse--tannish yellow.
Aerial mycelium--Moderate, grayish white to pale gray edged with medium gray. Sporulation good.
Soluble pigment--Very light brown.
Yeast Extract-Dextrose Salts Agar:
Vegetative growth--Tan.
Aerial mycelium--Moderate, white.
Soluble pigment--None.
Nutrient Agar:
Vegetative growth--Cream to tan.
Aerial mycelium--None.
Soluble pigment--None.
Skim Milk Agar:
Vegetative growth--Tan.
Aerial mycelium--None.
Soluble pigment--Medium brown.
Hydrolysis of casein -Cvood.
Litmus Milk:
Vegetative growth--Moderate growth ring, tan.
Peptonization, becoming slightly alkaline. Nutrient Tyrosine Agar:
Vegetative growth--Tan.
Aerial mycelium--None.
Soluble pigment--None.
No decomposition of tyrosine.
Calcium Malate Agar:
Vegetative growth--Reverse--cream-colored.
Aerial mycelium--White with a pale yellowish tone.
Soluble pigment-None.
Utilization of malate.
Nutrient Starch Agar:
Vegetative growth--Tan.
Aerial mycelium--None.
Soluble pigment-None.
Hydrolysis of starch--Good. Nutrient Gelatin Agar:
Vegetative growth--Tan.
Aerial mycelium--Sparse, whitish.
Soluble pigment--None.
Liquefaction of gelatin-Good. Peptone-Iron Yeast Extract Agar:
Vegetative growth--Tan.
Aerial mycelium--None.
Soluble pigment--None.
No hydrogen sulfide produced.
Melanin negative. Temperature Range:
28C. Good Growth 37C Moderate Growth 50C. No Growth Carbohydrate Utilization: The Streptomyces albogriseolus culture (MA-4256) was also tested for its ability to utilize or assimilate various carbohydrates by growing the microorganism in a basal synthetic medium (T. G. Pridham and D. Gottlieb, Journal of Bacteriology, Vol. 56, page 107, 1948) which contains 1% of the carbohydrate at 28C. for 3 weeks. The following table indicates the utilization or assimilation of these carbohydrate sources by the Streptomyces albogriseolus culture (MA-4256). The explanation of the symbols in the table are as follows: indicates good growth, 2 indicates poor growth and indicates no growth on the particular carbohydrate.
Carbohydrate Utilization (Pridham-Gottlieb Basal Medium 1% Carbohydrate) The foregoing description of the novel strain of S treptomyces albogriseolus is simply illustrative of the type of strains of microorganisms which can be used, and it should be understood that the present invention is not limited to organisms meeting these particular descriptions. This invention includes the use of other microorganisms, including strains of actinomycetes either isolated from nature or obtained by mutation as, for example, those obtained by natural selection or those produced by mutating agents, for example, X-ray irradiation, ultraviolet irradiation, nitrogen mustards and the like which, under suitable conditions, will afford the antibiotic products.
The antibiotics toyocamycin and cephamycin C are produced during the aerobic fermentation of suitable aqueous nutrient mediums under controlled conditions via inoculation with the Streptomyces albogriseolus culture [VIA-4256. Aqueous mediums such as those employed for the production of other antibiotics are also suitable for producing the antibiotics described above. Such mediums contain sources of carbon and nitrogen assimilable by the microorganism and inorganic salts.
In general, carbohydrates such as sugars, for example, glucose, arabinose, maltose, Xylose, mannitol and the like and starches such as grains, for example, oats, rye, corn starch, corn meal and the like can be used either alone or in combination as sources of assimilable carbon in the nutrient medium. The exact quantity of the carbohydrate source or sources utilized in the medium depend in part upon the other ingredients of the medium but, in general, the amount of carbohydrate usually varies between about 1% and 6% by weight of the medium. These carbon sources can be used individually or several such carbon sources may be combined in the medium. In general, any proteinaceous material may be used as a nitrogen source in the fermentation process. Suitable nitrogen sources include, for example, yeast hydrolysates, yeast autolysate, soybean meal, hydrolysates of casein, corn steep liquor, distillers solubles or tomato paste and the like. The sources of nitrogen, either alone or in combination, are used in amounts ranging from about 0.2 to 6% by weight of the aqueous medium. Among the nutrient inorganic salts which can be incorporated in the culture media are the customary salts capable of yielding sodium, potassium, ammonium, calcium, phosphate, sulfate, chloride, carbonate, and like ions.
Minor elements necessary for optimum growth and development of the organism can also be included in the culture medium. Such trace elements commonly occur as impurities in the other constituents of the medium in amounts sufficient to meet the growth requirements of the actinomycete employed in this invention.
Typical of the media which are suitable to be employed in the practice of the invention are those listed below. These media and others described in the examples which follow are merely illustrative of the wide variety of media which may be employed and are not intended to be limitative.
Medium 1:
Difco Yeast Extract 10.0 g. Glucose 10.0 g. Phosphate Buffer* 2.0 ml. MgSO 7H 0 0.05 g. Distilled water 1000.0 ml. Difco Agar 25.0 g.
Phosphate Bufierz" KH PO, 91.0 g. NA HPO, 95.0 g. Distilled water 1000.0 ml. Medium 11:
Beef Extract 3.0 g. NZ Amine* 10.0 g. Dextrose 10.0 g. NaCl 5.0 g. Distilled H O 1000.0 m1.
pH adjusted to 7.2 with NaOH an enzymatic digested casein Medium 111:
Dextrose 10.0 g. Asparagine 1.0 g. K HPO 0.1 g. MgSO, 7H O 0.5 g. Yeast Extract 0.5 g. Trace Element Mix No. 2* 10.0 ml. Distilled H O 1000.0 m1.
pH adjusted to 7.2 with NAOH Trace Element Mix No. 2:*
FeSO -7H O 1.0 g. MnSO, H O 1.0 g. CuCl 2H O 25.0 mg. CaCl 100.0 mg. H 56.0 mg. 1H,) MO-,O 41-1 0 19.0 mg. ZnSO, 7H O 200.0 mg.
-Cont1nued Distilled H O 1000.0 ml. Medium 1V:
V8 Juice 100.0 ml. Staleys 4S Soybean Meal 20.0 g. Dextrose 2.0 g. Agar 25.0 g. Distilled H O to 1000.0 ml.
pH 7.9-8.0 Medium V:
Yeast Autolysate (Ardamine) 10.0 g Glucose 10.0 g. Phosphate Buffer* 2.0 ml. MgSO, 7H 0 0.5 g. Distilled H O 1000.0 ml.
pH adjusted to 6.5 using NaOH Phosphate Buffer Solution:*
KH PO 91.0 g. Na i-1P0. 95.0 g. Distilled H O 1000.0 ml. Medium Vl:
Corn Steep Liquor (wet basis) 40.0 g. Dextrose 20.0 g. NaCl 2.5 g. MgSO 7H O 0.5 g
0.25% by volume (add to each flask invididually) Polyglycol2000 Distilled H 0 pH adjusted to 7.0 with NaOH Medium Vll:
Medium X:
Staleys 4S-Soybean Meal 30 Distillers Solubles 7 Cerelose 20. NaCl 2 CaCO (after pH to 7.0)
Distilled Water Medium Xl:
Amber Yeast No. 300
Distillers Solubles Distilled Water The fermentation is carried out at temperatures ranging from about 20C. to 37C., but for optimum results it is preferable to conduct the fermentation at tempera tures of from about 24C. to 32C. The pH of the nutrient mediums suitable for growing the Streptomyces albogriseolus culture (MA-4256) and producing the antibiotic products should be in the range of from about 6.0 to about 8.0.
Fermentation is conveniently carried out by inoculating a suitable nutrient medium with the antibioticproducing culture and permitting the fermentation to proceed at a constant temperature of about 28C. on a shaker for several days. At the end of the incubation period the mycelium is removed and the supernatant liquid is assayed.
In practice, this fermentation is conducted in a sterilized flask via a one, two, three or four stage seed development. The nutrient medium for the seed stage may be any suitable combination of carbon and nitrogen sources, as for example, any one of Media I-XI described above. The seed flask is shaken in a constant temperature chamber at about 28C. for a period of from 1 to about 3 days and a portion of the resulting growth is used to inoculate either a second stage seed or the production medium. Intermediate stage seed flasks, when used, are developed in essentially the same manner, that is, a portion of the contents of the flask are used to inoculate the production medium, the inoculated flasks are shaken at a constant temperature for several days and at the end of the incubation period the contents of the flasks are centrifuged to remove the mycelium. The supernatant liquid or broth is then concentrated and purified to afford the antibiotic materials.
For larger scale work, it is preferable to conduct the fennentation in suitable tanks provided with an agitator and a means of aerating the fermentation medium. According to this method, the nutrient medium is made up in the tank and sterilized by heating at temperatures of up to about C. Upon cooling, the sterilized medium is inoculated with the producing culture and the fermentation is permitted to proceed for a period of several days as, for example, from 2 to 4 days while agitating and/or aerating the nutrient medium and maintaining the temperature at about 28C. Through changes in inoculum development and changes in production medium, it is also possible to achieve a severalfold improvement in production and increase the potency of the antibiotics.
The concentration of antibiotic activity in the culture medium can be followed readily during the fermentation period by testing samples of the culture medium for their inhibitory activity against the growth of organisms known to be inhibited by the presence of the antibiotics produced in accordance with the practice of the invention. The organisms Vibrio percolans ATCC 8461 and Pseudomonas stutzeri ATCC 1 1607 have been found to be useful for this purpose. The testing of the samples can be carried out by the well-known turbidometric or disc-plate methods.
The examples which follow illustrate the procedures o this invention. However, the examples are illustrative only and it should be apparent to those having ordinary skill in the art that this invention includes other functionally equivalent products and methods for their preparation. Therefore, any modification of representative procedures exemplified which results in the formation of an identical product should be construed as constituting an analogous method. The claimed process is capable of wide variation and modification and, therefore, any minor departure therefrom or extension thereof is considered as being within the skill of the artisan and as falling within the scope of this invention.
EXAMPLE 1 A lyophilized tube of Streptomyces albogriseolus culture (MA-4256) was opened asceptically and the organism transferred to a sterile slant of Medium A.
The Medium A has the following composition:
Difco Agar 25.0 g. Yeast Autolysate (Ardamine) 10.0 .g. Glucose 10.0 g. Phosphate Buffer* 2.0 g. MgSO 7H O 0.05 g. Distilled Water 1000.0 ml.
pH 6.5 (adjust using a NaOH) Phosphate Buffer:*
Na 1-1PO 95.0 g.
Distilled Water 1000.0 ml.
The slant was incubated for seven days at 28C. The slant was stored in the cold for 2 weeks, at which time a sterile slant of Medium B was inoculated with a portion of the growth from the Medium A slant.
The Medium B has the following composition:
Difco Agar 25.0 g. Corn Starch* 15.0 g. L-Asparagine 1.0 g. Monosodium Glutamate 0.5 g. K HPO 0.1 g. MgSO, 711 0.5 g. Trace Element Mix No. 2** 10.0 ml. Difco Yeast Extract 0.5 g. NaCl 5.0 g. Distilled Water 1000.0 ml.
pH: adjust to 7.0 using NaOH Clinton Co. Corn Starch* Trace Element Mix No. 2:**
FeSO, 7H O 1000 mg. MnSO .4H,O 1000 mg. CuCl 2H,O 25 mg. CaCl 100 mg. H BO 56 mg. (NH Mo,O 4H O 19 mg. ZnSO. 7H O 200 mg. Distilled Water 1000 ml.
Autolysed Yeast; BYF series 300 (Amber Labs, inc.) 10.0 g. Distillers Solubles (Brown & Forman Co.) 20.0 g. Dextrose 10.0 g. CaCO 3.0 g. Distilled Water 1000 ml.
pH: adjust to 7.0 using NaOH The 2-liter flasks were shaken at 28C. on a 220 rpm rotary shaker with a 2-inch throw for 4 days. At the end of the incubation period the contents of the flasks were combined.
A sample of the pooled broth was centrifuged to remove the mycelium and the supernatent liquid assayed as follows: 1
The presence and concentration of cephamycin C in the broth was determined by standard agar diffusion assays performed with 0.5-inch filter paper discs soaked in the broth and set on the surface of assay plates containing 10 ml. of nutrient agar (Difco) plus 0.2% yeast extract (Difco) medium seeded with the bacterial inoculum. The assay organism employed was 'Vibrio percplans (ATCC 8461 Filter paper discs are immersed into the diluted broths and placed on the surface of agar-containing Petri dishes that had been inoculated with the assay organism Vibrio percolans (ATCC 8461 Also placed on these Petri dishes are discs that had been dipped previously in standard solutions containing known concentrations of cephamycin C. The discs were incubated overnight at 28C and the diameters of the zones of inhibition recorded. The concentration of cephamycin C in the fermented broth is calculated by interpolation from the standard curve which relates zone diameter with the known concentrations of standard cephamycin C solutions. The assays of broth harvested after fermentation for 4 days showed an inhibition zone of 31.5 mm. diameter on plates seeded with Vibrio percolans (ATCC 8461). The broth potency was 42 ug/ml. as cephamycin C.
EXAMPLE 2 Isolation of Cephamycin C The filtered broth (2 liters) obtained in accordance with Example 1 (pH 8.0) was adsorbed on 200 ml. of a strongly. basic anion exchange resin having a styrenedivinylbenzene matrix (Dowex 1 X 2 chloride cycle resin) and eluted with 5% aqueous sodium chloride. The eluate was collected in ml. fractions and assayed as described above. The active fractions of Dowex 1 eluate were combined and adjusted to pH 4.0 with dilute hydrochloric acid and adsorbed on 250 ml. of a strongly acidic cation exchange resin of the sulfonate type having a styrene-divinylbenzene matrix (Dowex 50 X 2 hydrogen cycle resin) at 25 ml./minute. The column was washed with 500 ml. of water and then eluted with 2% pyridine until the pH of the column effluent rose to pH 7 (1000 ml.). Assays of the spent fraction and eluate indicated none of the activity in the spent and 90% in the eluate. The eluate was identified as the pyridinium salt of cephamycin C.
The Dowex 5O eluate (700 ml.) was adjusted to pH 8.2 with dilute sodium hydroxide and concentrated tov remove pyridine resulting in a final volume of 50 ml. The pH was then adjusted to 7.0 with dilute HCl and further concentrated to dryness to yield 780 mg. of crude product.
The crude product from Dowex 50 was dissolved in 6 ml. of H 0 for chromatography on Dowex 1 X 2 resin buffered with 0.1M pyridine/HCl pH 5 .0.
To a 1.4 X 87 cm. (134 ml.) resin bed, 3 ml. of sample was applied and developed with the above buffer at 1 ml./min. collecting 5 ml. fractions. A Mecco-matic differential refractom'eter was used to monitor the effluent stream.
A single peak of bioactivity against Vibrio percolans ATCC 8461 which coincided with a refractive index peak was observed between fractions 76 and with the maximum at fraction 84. The K was calculated as 4.6 using the formula Kb (Ve 0.4 (Vr))/0.6 (Vr) which is in good agreement with previously observed values for cephamycin C.
Fractions 81 to 101 were combined and the pH adjusted to 8.2 with dilute sodium hydroxide. The solution was concentrated to a small volume to remove pyridine and the pH adjusted from 7.5 to 7.0 with HCl.
The solution was then concentrated to dryness, yielding a 775 mg. residue.
The above residue was taken up in 1.5 ml. of 1% nbutyl alcohol and desalted using a 1.4 X 84.5 cm. column of Bio-Gel P-2. The gel was developed with 1% nbutyl alcohol at 0.25 mL/min. collecting 2 ml. fractions. The effluent stream was monitored as previously stated. The desired fractions were located by bio-assay against Vibrio percolans ATCC 8461. Fractions 39 to 44 were combined and concentrated to dryness, yielding 9.0 mg.
The potencies of the samples obtained were deter mined by comparison with a standard sample of cephamycin C. Bio-assay and UV measurements indicated that the samples were approximately 50% pure cephamycin C.
Paper strip chromatography was carried out using Whatman No. 1 paper and n-butyl alcohol, acetic acid, methyl alcohol, water (4:1:1:2). The compound was detected by bioautographing against Vibrio percolans ATCC 8461 and Pseudomonas stutzeri ATCC 11607.
The major component of NRRL 5735 (Rf 0.22) with activity against Vibrio percolans ATCC 8461 cannot be distinguished from cephamycin C.
EXAMPLE 3 Isolation of Toyocamycin Six liters of filtered broth (pH 7.6) obtained in accordance with Example I was adsorbed on 400 ml. of Dowex 1 X 2 Cl cycle resin. The adsorbate was washed with 500 ml. of water and then eluted with 70% aqueous methanol. A 500 ml. eluate fraction was collected and concentrated to dryness.
The above residue was dissolved in 9 ml. of hot methanol and filtered. The clear solution was allowed to cool to room temperature and then 21 ml. of water was added with stirring. The solution was placed in the refrigerator overnight to crystallize. The crystals were removed by filtration and dried one hour at 50C. and 0.01 mm. of pressure. Yield 128 mg. Based on an estimated 80% overall yield, the above filtered broth contained approximately pug/ml. of toyocamycin.
A comparison of the ultra-violet spectra of the isolated crystalline material and that published for toyocamycin is tabulated below:
Calculated for Elemental Analysis* 12 l3 5 4 Found C 49.45 C 49.50 H 4.67 H 4.50 N 23.76 N 24.07 0 diff. 22.12 0 22.0
Weight loss C. 1 hr. 6.83%
We claim:
1. A method of producing an antibiotic mixture comprised of cephamycin C and toyocamycin which method comprises cultivating a cephamycin C and toyocamycin producing strain of Streptomyces albagriseolus in a culture medium containing assimilable sources of carbon and nitrogen under aerobic conditions until a substantial amount of said antibiotics are produced by said organism in the culture medium.
2. The method of claim 1 wherein the organism is Streptomyces albogriseolus NRRL 5735.
3. A method according to claim 1 additionally comprising recovering cephamycin C from said culture medium.
4. A method according to claim 1 additionally comprising recovering toyocamycin from said culture medium.
5. A method of producing the antibiotic cephamycin C which method comprises cultivating a cephamycin C producing strain of Streptomyces albogriseolus in a culture medium containing assimilable sources of carbon and nitrogen under aerobic conditions until a substantial amount of said antibiotic is produced by said organism in the culture medium.
6. The method of claim 5 wherein the organism is Streptomyces albogriseolus NRRL 5735.
7. A method according to claim 5 additionally comprising recovering cephamycin C from said culture medium.
8. A method of producing the antibiotic toyocamycin which method comprises cultivating a toyocamycin producing strain of Streptomyces albogriseolus in a culture medium containing assimilable sources of carbon and nitrogen under aerobic conditions under a substantial amount of said antibiotic is produced by said organism in the culture medium.
9. The method of claim 8 wherein the organism is Streptomyces albogriseolus NRRL 5735.
10. A method according to claim 8 additionally comprising recovering toyocamycin from said culture medium.
UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3 914 5 DATED October 21, 1975 'NVENTOR) 1 EDWARD o. STAPLEY & JUSTO M. MA'IA it is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 10, Claim 8 line 5, should read as follows:
"and nitrogen under aerobic conditions until a substan".
Signed and Scaled this third D8) of February 1976 [SEAL] AIICSI.
RUTH C. MASON C. MARSHALL DANN Arresting Officer Commissioner ufParents and Trademarks UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3, 14 5 DATED October 21, 1975 INVENTWS) I EDWARD o. STAPLEY & JUSTO M. MA'I'A It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 10, Claim 8 line 5, should read as follows:
"and nitrogen under aerobic conditions until a substan".
Signed and Scaled this third D ay Of February 1 976 [SEAL] A ttest:
RUTH C. MASON C. MARSHALL DANN Arresting Officer Commissioner oflarems and Trademarks
Claims (9)
1. A METHOD OF PRODUCING AN ANITIBIOTIC MIXTURE COMPRISED OF CEPHAMYCIN C AND TOYOCAMYCIN WHICH METHOD COMPRISES CULTIVATING A CEPHAMYCIN C AND TOYOCAMYCIN PRODUCING STRAIN OF STREPTOMYCES ALBOGRISEOLUS IN A CULTURE MEDIUM CONTAINING ASSIMBIABLE SOURCES OF CARBON AND NITROEN UNDER AEROBIC CONDITION UNTIL A SUBSTANTIAL AMOUNT OF SAID ANTIBIOTICS ARE PRODUCED BY SAID ORGANISM IN THE CULTURE MEDIUM. 2. HE METHOD OF CLAIM 1 WHEREIN THE ORGANISM IS STREPTOMYCES ALBOGRISEOLUS NRRL 5735.
3. A method according to claim 1 additionally comprising recovering cephamycin C from said culture medium.
4. A method according to claim 1 additionally comprising recovering toyocamycin from said culture medium.
5. A METHOD OF PODUCING THE ANTIBIOTIC CEPHAMYCIN C WHICH MTHOD COMPRISES CULTIVATING A CEPHAMYCIN C PRODUC ING STRAIN OF STREPTOMYCES ALBOGRISEOLUS IN A CULTURE MEDIUM CONTAINING ASSIMILABLE SOURCES OF CARBON AND NITROGEN UNDER AEROBIC CONDITIONS UNTIL A SUBSTANTIAL AMOUNT OF SAID ANTIBIOTIC IS PRODUCED BY SAID ORGANISM IN THE CULTURE MEDIUM.
6. The method of claim 5 wherein the organism is Streptomyces albogriseolus NRRL 5735.
7. A method according to claim 5 additionally comprising recovering cephamycin C from said culture medium.
8. A METHOD OF PRODUCING THE ANTIBIOTIC TOYOCAMYCIN WHICH METHOD COMPRISES CULTIVATING A TOYOCAMAYCIN PRODUCING STRAIN OF STREPTOMYCES ALBOGRISEOLUS IN A CULTURE MEDIUM CONTAINING ASSIMILABLE SOURCES OF CARBON AND NITROGEN UNDER AEROBIC CONDITIONS UNDER A SUBSTANTIAL AMOUNT OF SAID ANTIBIOTIC IS PRODUCED BY SAID ORGANISM IN THE CULTURE MEDIUM.
9. The method of claim 8 wherein the organism is Streptomyces albogriseolus NRRL 5735.
10. A method according to claim 8 additionally comprising recovering toyocamycin from said culture medium.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US367661A US3914158A (en) | 1973-06-06 | 1973-06-06 | Antibiotic production |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US367661A US3914158A (en) | 1973-06-06 | 1973-06-06 | Antibiotic production |
Publications (2)
Publication Number | Publication Date |
---|---|
USB367661I5 USB367661I5 (en) | 1975-01-28 |
US3914158A true US3914158A (en) | 1975-10-21 |
Family
ID=23448093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US367661A Expired - Lifetime US3914158A (en) | 1973-06-06 | 1973-06-06 | Antibiotic production |
Country Status (1)
Country | Link |
---|---|
US (1) | US3914158A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3977942A (en) * | 1975-11-21 | 1976-08-31 | Merck & Co., Inc. | Fermentation of cephamycin C |
US4075061A (en) * | 1976-02-19 | 1978-02-21 | Glaxo Laboratories Limited | Method for producing cephalosporins |
US4164447A (en) * | 1976-02-19 | 1979-08-14 | Glaxo Laboratories Limited | O-Transcarbamoylase |
WO2004106347A1 (en) | 2003-05-28 | 2004-12-09 | Dsm Ip Assets B.V. | Cephem compound |
CN101940211A (en) * | 2010-03-19 | 2011-01-12 | 中国计量学院 | Application of toyocamycin in preventing and curing cucumber wilt |
CN101961015A (en) * | 2010-03-19 | 2011-02-02 | 中国计量学院 | Application of toyocamycin in preventing and treating tomato early blight |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522650A (en) * | 1978-08-07 | 1980-02-18 | Takeda Chem Ind Ltd | Novel bioactive substance |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3116222A (en) * | 1962-10-05 | 1963-12-31 | Pfizer & Co C | Process for preparing toyocamycin |
US3801464A (en) * | 1972-02-09 | 1974-04-02 | Lilly Co Eli | Antibiotic a16886 and process for production thereof |
-
1973
- 1973-06-06 US US367661A patent/US3914158A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3116222A (en) * | 1962-10-05 | 1963-12-31 | Pfizer & Co C | Process for preparing toyocamycin |
US3801464A (en) * | 1972-02-09 | 1974-04-02 | Lilly Co Eli | Antibiotic a16886 and process for production thereof |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3977942A (en) * | 1975-11-21 | 1976-08-31 | Merck & Co., Inc. | Fermentation of cephamycin C |
US4075061A (en) * | 1976-02-19 | 1978-02-21 | Glaxo Laboratories Limited | Method for producing cephalosporins |
US4164447A (en) * | 1976-02-19 | 1979-08-14 | Glaxo Laboratories Limited | O-Transcarbamoylase |
WO2004106347A1 (en) | 2003-05-28 | 2004-12-09 | Dsm Ip Assets B.V. | Cephem compound |
CN101940211A (en) * | 2010-03-19 | 2011-01-12 | 中国计量学院 | Application of toyocamycin in preventing and curing cucumber wilt |
CN101961015A (en) * | 2010-03-19 | 2011-02-02 | 中国计量学院 | Application of toyocamycin in preventing and treating tomato early blight |
CN101961015B (en) * | 2010-03-19 | 2013-04-24 | 中国计量学院 | Application of toyocamycin in preventing and treating tomato early blight |
CN101940211B (en) * | 2010-03-19 | 2013-04-24 | 中国计量学院 | Application of toyocamycin in preventing and curing cucumber wilt |
Also Published As
Publication number | Publication date |
---|---|
USB367661I5 (en) | 1975-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US2653899A (en) | Erythromycin, its salts, and method of preparation | |
US2482055A (en) | Aureomycin and preparation of same | |
SU578014A3 (en) | Method of preparing p,q,r and u rifamycin | |
US3914158A (en) | Antibiotic production | |
IL24529A (en) | Process for preparing cephalosporin derivatives | |
US3914231A (en) | ({31 )(Cis-1,2-epoxypropyl)-phosphonic acid and salts thereof | |
US3770590A (en) | Fermentation process | |
CA1225053A (en) | Methods and compounds and compositions for treating protozoal infections with a novel antibiotic | |
KR870001987B1 (en) | Process for preparing enduracidin | |
US3853709A (en) | Process for preparing nebramycin factors ii and vii | |
IL45888A (en) | Process for producing deacetoxycephalosporin c | |
DE2166462A1 (en) | 7 BETA - (D-5-AMINO-5-CARBOXYVALERAMIDO) 3- (ALPHA-METHOXYCINNAMOYLOXYMETHYL) -7-METHOXY-3-CEPHEM-4-CARBONIC ACID COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND SOLID COMPOUNDS | |
US3616237A (en) | Method of preparing thiogriseofulvins | |
US3769169A (en) | Fermentation process | |
US4036696A (en) | Preparation of antibiotics by fermentation | |
US4376761A (en) | Homocitric acid oligoriboside derivative for prevention of dental caries | |
US4267274A (en) | Streptomyces mediterranei mutant capable of production of rifamycin B | |
US3991183A (en) | Antibiotic produced by a species of micromonospora | |
US3925155A (en) | Preparation of 6-aminopenicillanic acid 1-oxide | |
US3901880A (en) | (s)-alanyl-3-(+60 -(s)-chloro-3-(s)-hydroxy-2-oxo-azetidinylmethyl)-(s)-alanine | |
US3239428A (en) | Preparation of 6-aminopenicillanic acid by arthrobacter viscosus | |
US3975235A (en) | Process for the production of cephamycin type antibiotic substances | |
EP0034009B1 (en) | Process for preparing polyether antibiotic | |
US3598819A (en) | Quinoxaline derivatives and process for producing the same | |
US3785927A (en) | Process for converting(-)reticuline to(+)salutaridine |